GLP‐1 agonists, which are widely used for the treatment of diabetes mellitus, have recently been proposed to ameliorate muscle wasting by suppressing myostatin and muscle atrophic factors (such as atrogin‐1 and muscle RING‐finger protein‐1 (MuRF‐1)), and enhancing myogenic factors including MyoG and MyoD. 40Pharmacologic GLP‐2‐stimulation promotes gut‐specific growth, enhances intestinal epithelial function and alleviates malnutrition, likely secondary contributes to the gut‐specific pro‐absorptive effects.41 The gene discussed is GCG; the disease is diabetes mellitus.